TriSalus Life Sciences, Inc.

TLSI Nasdaq SEC CIK 1826667
Follow TriSalus Life Sciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $12.9M +11.3% vs same quarter last year
Net income −$8.9M +18.1% vs same quarter last year
EPS, diluted −$0.15 +84.4% vs same quarter last year
Operating cash flow −$5.3M −42.2% vs same quarter last year
Revenue by quarter
$8.3M
$9.2M
$11.2M
$11.6M
$13.2M
$8.9M
$11.4M
$12.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50MFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$45.2M−$39.2M
FY24$29.4M−$30M
FY23$18.5M−$59.4M
FY22$12.4M−$47.2M
FY21-$4.8M
FY20--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−400%−200%0%200%FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2584.6%−59.7%−86.9%
FY2486.1%−122.9%−102.1%
FY2385.9%−294.3%−320.7%
FY2281.8%−293.9%−380.6%
FY21---
FY20---
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$18.9M
FY24−$41.2M
FY23−$51.2M
FY22−$33M
FY21-
FY20-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • TriSalus Life Sciences
  • Healthcare median
−400%−300%−200%−100%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearTriSalus Life SciencesHealthcare median
FY25−86.9%−30.6%
FY24−102.1%−47%
FY23−320.7%−58%
FY22−380.6%−80.4%
FY21-−71.8%
FY20-−62.2%